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Introduction 
Melasma is an acquired hyperpigmentation that is 
characterized by bilateral irregular brown macules 
and patches on sun exposed areas of the face and 
less frequently, the forearms [1]. It is most commonly 
found in darker skinned females — typically Asian or 
Hispanic women — with Fitzpatrick skin types III-IV. 
It is triggered by a variety of factors including sun 
exposure, genetics, and female sex hormones [2]. 
The pathology of melasma is complex although it 
was initially thought to involve only melanocytes. 
Evolving research points to a more heterogeneous  
pathogenesis involving an interplay of keratinocytes, 
mast cells, gene regulation abnormalities, increased 
vascularization, and basement membrane disruption 
[3]. It is essential that clinicians are familiar with the 
evolving pathogenesis of melasma, as this may aid in 
successful combination treatment options for this 
notoriously difficult and relapsing condition. This 
review aims to provide a summary of the more novel 
pathological findings and latest investigational 
therapies. 
 
Discussion 
Publications describing melasma pathogenesis were 
primarily found through a PubMed literature search. 
Keywords included: melasma, pathology, 
melanogenesis, melanocytes, keratinocytes, mast 
cells, ultraviolet (UV) radiation, basement 
membrane, vascularization, prostaglandins, 
estrogen, progesterone, therapeutics, and 
tranexamic acid. Several articles were reviewed for 
relevancy from 1981 to 2018 and references of the 
selected articles were also searched for relevant 
articles. A total of 35 references were included. 
Literature included was of a variety of types 
including basic science research, randomized 
controlled trials, commentaries, and reviews. 
Melanocytes 
The increase in the amount of melanin production in 
melasma is well accepted. However, whether or not 
this increase is accompanied by a quantitative 
increase in melanocytes is debated [4, 5]. The specific 
mechanisms behind increased melanin deposition 
are still being elucidated. It has been shown that UV 
Abstract 
Melasma is an acquired hyperpigmentation disorder 
most commonly affecting females with darker skin 
types. It is triggered by several factors including sun 
exposure, genetic influences, and female sex 
hormones. The pathology of melasma extends 
beyond melanocytes and recent literature points to 
interactions between keratinocytes, mast cells, gene 
regulation abnormalities, neovascularization, and 
disruption of basement membrane. This complex 
pathogenesis makes melasma difficult to target and 
likely to recur post treatment. A better understanding 
of the latest pathological findings is key to 
developing novel and successful treatment options. 
This review aims to provide a summary of the more 
novel pathological findings and latest investigational 
therapies. 
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radiation leads to an upregulation of melanocyte-
stimulating hormone (MSH) receptors — also known 
as melanocortin-1 receptors (MC1-R) — on 
melanocytes, allowing for greater binding of the 
hormones and therefore more melanin production 
[6]. Proopiomelanocortin (POMC) is cleaved to 
produce the peptides -melanocyte stimulating 
hormone (-MSH) and adrenocorticotropic 
hormone (ACTH) in response to UV [7]. When these 
peptides bind to and activate MC1-R, they increase 
levels of protein kinase A (PKA), which 
phosphorylates the cAMP response element (CREB), 
(Figure 1). 
cAMP response element is a transcription factor for 
microphthalmia associated transcription factor 
(MITF), a key regulator in the melanin synthesis 
pathway. Microphthalmia associated transcription 
factor controls the expression of tyrosinase, an 
enzyme responsible for several steps in 
melanogenesis [8]. UV radiation is also shown to 
endogenously generate 1,2-diacylglycerols (DAGs), a 
type of second messenger, from plasma membrane 
phospholipids of melanocytes via phospholipase C 
and D (PLC and PLD) pathways. These DAGs go on to 
activate tyrosine and therefore increase 
melanogenesis (Figure 1), [9].  
The tumor suppressor protein p53 may also play a 
role in UV-induced melanogenesis. This protein 
upregulates POMC production in keratinocytes post 
UVB damage, which leads to increased melanin 
production. In addition, the protein also increases 
transcription of hepatocyte nuclear transcription 
factor-1alpha (HNF-1alpha), which induces 
tyrosinase downstream to increase melanin 
Figure 1. Flow diagram showing the total number of mobile apps found from the Apple App Store and the number of apps excluded 
from analysis (including reason for removal). 
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production even in the absence of keratinocytes 
(Figure 1), [8]. Although the above pathways induce 
melanogenesis in all skin, the response to UV light is 
exaggerated and expression of -MSH is sustained in 
melasma lesions, augmenting the production of 
melanin [7]. 
Solar Elastosis and Photoaging 
Solar elastosis refers to the accumulation of 
abnormal elastic tissue in the dermis resulting from 
chronic sun exposure or photoaging. Melasma 
patients have been found to have high levels of solar 
elastosis in affected skin. In addition, histological 
analysis shows that melasma skin tends to have 
thicker and more curled and fragmented elastic 
fibers when compared to normal skin [3]. 
Ultraviolet B exposure can stimulate keratinocytes to 
increase melanocyte and therefore, melanin 
production by secreting various growth factors, 
cytokines, and hormones including inducible nitric 
oxide synthase or iNOS [10]. UVB irradiation also 
increases plasmin production by keratinocytes. This 
enzyme leads to higher levels of arachidonic acid 
and alpha-MSH and therefore stimulates the melanin 
synthesis pathway [11]. These factors all lead to 
hyperpigmentation of the affected skin. 
Furthermore, it has been suggested that even visible 
light may play a role in the pathogenesis of melasma, 
especially in darker skin types (Fitzpatrick types IV-
VI), by interacting with the opsin 3 sensor (Figure 1), 
[12]. 
Mast Cells and Neovascularization 
Numbers of mast cells are higher in melasma skin 
than in unaffected skin [8]. UV exposure triggers the 
release of histamine from these mast cells, leading to 
downstream effects [13]. Histamine binding at the 
H2 receptor activates the tyrosinase pathway and 
induces melanogenesis. This finding may help 
elucidate the link between the inflammatory process 
in UV radiation and the hyperpigmentation that 
follows [14]. 
In addition, UV radiation also increases the 
production of mast cell tryptase, which activates 
matrix metalloproteinase (MMP) precursors. These 
active enzymes then go on to degrade type IV 
collagen and damage the basement membrane. 
Granzyme B, released directly by mast cells, further 
damages the extracellular matrix (ECM). Tryptase 
may also contribute to solar elastosis by triggering 
the production of elastin [3]. 
Finally, mast cells induce hypervascularization, 
another prominent clinical finding in melasma, by 
secreting proteins such as vascular endothelial 
growth factor (VEGF), fibroblast growth factor-2 
(FGF-2), and transforming growth factor-B (TGF-B). 
These angiogenic factors increase the size, density, 
and dilatation of vessels in affected skin, and present 
another therapeutic target when treating melasma 
(Figure 1), [2, 3]. 
Basement Membrane Damage 
Basement membrane abnormalities play a key role in 
melasma pathology. As described above, UV 
damage activates MMP2 and MMP9 to degrade type 
IV and VI collagen in the basement membrane [3]. 
Cadherin 11, an adhesion molecule that is 
upregulated in melasma skin, can then mediate 
interaction between fibroblasts and melanocytes 
and promote melanogenesis [15]. Cadherin 11 is also 
responsible for upregulating MMP1 and MMP2 
expression, leading to further collagen degradation 
and accumulation of elastotic material in melasma 
skin. These effects may even be independent of UV 
irradiation [15]. Basement membrane damage also 
allows the movement of melanocytes and melanin 
granules down into the dermis, which contributes to 
the persistent and recurring nature of melasma. 
Therefore, trauma induced by lasers or any therapies 
that further aggravate the basement membrane may 
worsen the disease. Similarly, restoration of the 
basement membrane may limit recurrence (Figure 
1), [3].  
Dermal Inflammation 
Prolonged UV radiation causes dermal inflammation 
and activates fibroblasts. These cells then secrete 
stem cell factor (SCF), which may diffuse into and 
induce melanogenesis in the overlying epidermis 
[16]. Likewise, levels of stem cell growth factor 
receptor, also known as c-kit, are also upregulated in 
melasma lesions. When c-kit binds to SCF, it activates 
the tyrosine kinase pathway responsible for 
melanogenesis [17]. Dermal inflammation is also 
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characterized by increased levels of COX-2 and 
prostaglandins, further stimulating melanocytes 
(Figure 1), [18]. 
Hormonal Influence 
Estrogen has also been shown to play a role in 
melasma pathogenesis, which explains its increased 
prevalence among post-pubertal women, oral 
contraceptive users, and pregnant women. Studies 
have shown an increased number of estrogen 
receptors in the dermis and of progesterone 
receptors in the epidermis of melasma lesions [19, 
20]. Binding of estrogen to its receptors on 
melanocytes and keratinocytes can activate 
tyrosinase and MITF pathways to induce melanin 
production [21]. In addition, increased expression of 
the PDZ domain protein kidney 1 (PDZK1), which 
regulates ion exchangers, in melasma lesions could 
help mediate interactions between estrogen and ion 
exchangers to increase melanogenesis and 
melanosome transfer [22]. Estrogen’s role presents a 
unique target for melasma therapy. 
Novel Approaches to Therapy 
Melasma’s complex pathology and recurring nature 
make it difficult to target therapeutically [1]. 
Traditionally, melasma has been treated with topical 
agents, including hydroquinone (which inhibits 
tyrosinase), tretinoin, corticosteroids, and 
combination creams with varying formulations 
(Table 1). Hydroquinone has long been the 
conventional treatment, but the concern over its side 
effects have prompted the use of potentially safer 
alternatives. Current therapies include topical 
agents, chemical peels, laser and light treatments, 
and systemic agents [23]. 
Tranexamic acid (TXA), a plasmin inhibitor, has 
gained popularity as a systemic therapy for melasma 
and is available in oral, topical, and injectable forms. 
Plasmin increases arachidonic acid and 
prostaglandin levels in keratinocytes, leading to 
increased melanogenesis. Furthermore, plasmin 
frees ECM-bound VEGF, promoting angiogenesis 
[24]. Tranexamic acid is therefore one of the few 
Table 1. Melasma pathogenesis and corresponding medical/experimental therapies 
Component 
Mechanism of 
pathogenesis Therapies 
Level of 
Evidence Reference 
Tyrosine activation Increases melanogenesis 
Hydroquinone 
Azelaic Acid 
Glycolic acid 
siRNA agents 
Combination creams 
(*includes retinoid and 
steroid) 
Proton-pump inhibitors 
(block copper acquisition 
by tyrosinase, which leads 
to its degradation) 
2a 
1b 
2b 
2b 
1b 
 
 
Proposed 
therapy 
Ennes et al. [31] 
Balina LM and Graupe K [32] 
Sarkar et al. [33] 
Xiang Y et al. [27] 
Nordlund et al. [34] 
 
 
Matsui MS et al. [29] 
UVB-induced 
Keratinocyte 
stimulation 
Increases melanocyte 
production 
Retinoids 1a Griffiths CE et al. [35] 
Neovascularization Growth-factor induced angiogenesis Tranexamic acid 1b Atefi et al. [25] 
cAMP accumulation 
and CREB 
phosphorylation 
Controls downstream 
melanin synthesis 
pathways 
Metformin 
Proposed 
therapy Lehraiki et al. [28] 
Hormonal influence 
Binding of estrogen 
activates downstream 
melanogenesis 
pathways 
Estrogen antagonist 
Proposed 
therapy Cohen PR [21] 
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treatments to target the neovascularization present 
in melasma. A recent double-blinded clinical trial 
showed topical TXA to be as efficacious as 
hydroquinone in reducing the mean Melasma Area 
and Severity Index (MASI) score, with fewer side 
effects [25]. In another placebo-controlled double-
blinded trial, oral TXA was shown to be superior to 
the placebo for the treatment of moderate-to-severe 
melasma with minimal side effects [26]. 
Recent developments in melasma therapy include 
specific agents targeting various aspects of melasma 
pathology. Therapeutic alternatives to traditional 
topicals, such as small interfering ribonucleic acid 
(siRNA) agents, have been investigated. 
Microphthalmia associated transcription factor-
siRNA administered as a transdermal peptide targets 
and inhibits the tyrosinase pathway of 
melanogenesis in a time-dependent manner with no 
major side effects. This novel option also shows 
promise in melanoma treatment and is safe enough 
to use daily [27]. Metformin, an antidiabetic drug 
which acts by decreasing cAMP levels, has been 
shown to decrease melanin content in melanocytes 
by inhibiting downstream synthesis pathways [28]. 
Proton pump inhibitors (PPIs) such as omeprazole 
may also inhibit melanogenesis when applied 
topically. It is hypothesized that PPIs interfere with 
ATP7A, blocking copper acquisition by tyrosinase, 
which leads to its degradation and therefore reduces 
melanogenesis [29]. Most recently, a combination 
topical therapy has been suggested which combines 
an estrogen and VEGF antagonist, targeting both 
melanogenesis and angiogenesis [22]. 
Laser and light treatments for melasma, including 
intense pulsed light, target excess pigment in the 
skin but do not alter the underlying pathology of the 
disease. As a result, recurrence is common when 
laser is used as monotherapy. In addition, high 
intensity lasers can further degrade the basement 
membrane and allow descent of melanin into the 
dermis as mentioned above [3]. 
Regardless of the treatment modality chosen, sun 
protection is crucial to prevent new lesions and avoid 
worsening existing melasma [23]. The current 
recommendation is that patients use a broad-
spectrum UVA/UVB sunscreen with at least SPF30 
daily, preferably with a physical blocking agent such 
as zinc oxide or titanium dioxide. Behavioral 
measures such as wearing wide-brimmed hats or 
avoiding peak sunlight hours may also help [23]. 
Recent studies also show that a sunscreen that 
blocks visible light in addition to UV light may further 
improve melasma lesions and increase response to 
traditional lightening agents such as hydroquinone 
[30]. 
 
Conclusion 
In conclusion, melasma is a facial hyperpigmentation 
condition with a varied and evolving pathology. 
Increased melanogenesis, extracellular matrix 
alterations, inflammation, and angiogenesis all play 
a role in the development of melasma. The 
multifactorial nature of the disease makes it difficult 
to treat and likely to recur. A better understanding of 
the pathology is key to developing novel and specific 
therapeutic options. 
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